Maxim Group analyst Allen Klee reiterated a Buy rating on Marpai (MRAI – Research Report) yesterday and set a price target of $3.00. The company’s shares closed yesterday at $0.94.
According to TipRanks, Klee is an analyst with an average return of -24.8% and a 20.48% success rate. Klee covers the Technology sector, focusing on stocks such as Research Solutions, Marpai, and CareCloud.
Currently, the analyst consensus on Marpai is a Moderate Buy with an average price target of $3.00.
See the top stocks recommended by analysts >>
MRAI market cap is currently $19.21M and has a P/E ratio of -0.80.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Marpai Inc operates as a health plan company. It offers a health plan services system that addresses the problems of healthcare past and enables companies to provide healthcare to employees.
Read More on MRAI:
